Meta‐analysis reveals that rheumatoid arthritis is associated with worse clinical outcomes among patients with COVID‐19

Author:

Zhang Guangmin12,Liu Jiane12,Wang Jing3,Wang Zheng12ORCID,Zhang Jing3,Ding Yu2,Tang Xiuming2,Wang Wei2,Liu Jianxin2,Liu Yifei4,Liu Jing5,Xu Xiaohui12

Affiliation:

1. Department of Genetics and Cell Biology, Basic Medical College Qingdao University Qingdao Shandong China

2. Department of Reproductive Medicine The Affiliated Hospital of Qingdao University Qingdao Shandong China

3. Department of Rheumatology Haiyang People's Hospital Yantai Shandong China

4. Department of Obstetrics, Gynaecology, and Reproductive Sciences, School of Medicine Yale University New Haven Connecticut USA

5. Department of Rheumatology Qingdao Jimo People's Hospital Qingdao Shandong China

Abstract

AbstractPatients with rheumatoid arthritis (RA) are reported to be more vulnerable to coronavirus disease 2019 (COVID‐19), so clinical severity is a particular concern for them. This meta‐analysis was performed to evaluate the clinical outcomes in RA patients with COVID‐19. A systematic literature search was performed in electronic databases for relevant articles published from January 2020 to October 2022. We extracted necessary relevant data and Egger's test was used to evaluate the risk of publication bias. This meta‐analysis included 9 studies with a total of 12 339 RA patients with COVID‐19 and 685 982 non‐RA patients with COVID‐19. We found serious adverse outcomes in RA patients with COVID‐19, including the rates of severity (OR: 1.59, 95% CI: 1.23–2.05, p = .0004), hospitalization (OR: 1.73, 95% CI: 1.55–1.92, p < .00001), mortality (OR: 1.92, 95% CI: 1.67–2.20, p < .00001), mechanical ventilation (OR: 1.64, 95% CI: 1.47–1.84, p < .00001), despite no significant difference observed in ICU admission (OR: 1.37, 95% CI: 0.95–1.98, p = .09). Our data suggests that RA patients had an increased risk of adverse clinical outcomes with COVID‐19 infection.

Funder

Natural Science Foundation of Shandong Province

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3